Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Clinical trial NCT03484819 · COMPLETED

Trial details

NCT number: NCT03484819
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Diffuse Large B-Cell Lymphoma Recurrent Primary Mediastinal Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Primary Mediastinal Large B-Cell Lymphoma

Start date: 2019-12-13
Primary completion: 2022-11-18
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.